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Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune 
disorder that commonly involves the kidney. Early identification of kidney involvement, 
assessing treatment-response and predicting outcome are important clinical challenges. Here, 
we assessed the potential utility of interval kidney biopsy in AAV. 
Methods
In a tertiary referral centre with a dedicated vasculitis service, we identified patients with AAV 
who had undergone interval kidney biopsy, defined as a repeat kidney biopsy (following an 
initial biopsy showing active AAV) undertaken to determine the histological response in the 
kidney following induction immunosuppression. We analysed biochemical, histological and 
outcome data, including times to kidney failure and death for all patients. 
Results
We identified 57 patients with AAV who underwent at least one interval kidney biopsy (59 
interval biopsies in total; median time to interval biopsy ~130 days). Of the 59 interval biopsies 
performed, 24 (41%) patients had clinically suspected active disease at time of biopsy which 
was confirmed histologically in only 42% of cases; 35 (59%) patients were in clinical disease-
remission, and this was correct in 97% of cases. The clinician’s impression was incorrect in 1 
in 4 patients. Hematuria at interval biopsy did not correlate with histological activity. Interval 
biopsy showed fewer acute lesions and more chronic damage compared to initial biopsy and 
led to immunosuppressive treatment-change in 75% (44/59) of patients. Clinical risk prediction 
tools tended to operate better using interval biopsy data.  
Conclusion
Interval kidney biopsy is useful for determining treatment-response and subsequent disease 
management in AAV. It may provide better prognostic information than initial kidney biopsy 
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and should be considered for inclusion into future clinical trials and treatment protocols for 
patients with AAV.  
Graphical Abstract
Key words: ANCA vasculitis; interval kidney biopsy; hematuria
Key messages
 Interval kidney biopsy provides important information that guides clinical management 
of patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis 
(AAV).
 Hematuria correlates poorly with disease activity within the kidney. 
 Current renal risk prediction tools might operate more effectively using interval biopsy 
parameters.








































































Systemic vasculitis associated with autoantibodies to neutrophil cytoplasm antigens (ANCA), 
ANCA-associated vasculitis (AAV), is a rare autoimmune disorder characterized by leucocyte 
infiltration and necrosis of predominantly the small vessels.1 Kidney involvement is seen in 
two-thirds of patients, classically as a pauci-immune necrotizing glomerulonephritis with 
crescents.2 Induction immunosuppressive treatment for AAV with renal involvement typically 
involves glucocorticoids alongside cyclophosphamide or rituximab.3 Once a patient attains 
disease-remission, there follows a course of maintenance immunosuppression.
Identifying AAV early, assessing its response to treatment, and risk-stratifying patients at 
greatest long-term risk remain important clinical challenges. In those with renal involvement, 
the measurement of kidney function using serum creatinine is often inadequate because 
substantial renal damage can occur before function is impaired to a detectable extent.4, 5 
Furthermore, changes in serum creatinine concentration during follow-up may be due to 
changes in vasculitis disease activity or due to glomerular scarring or tubular injury from 
infections or medications, scenarios that require different clinical management. Other 
commonly used measures such as hematuria, circulating C-reactive protein (CRP) and serum 
ANCA titre lack specificity and sensitivity and do not adequately reflect disease activity.6, 7 
Recent data suggest that glucocorticoid-sparing,8, 9 or indeed glucocorticoid-free,10 regimens 
are able to treat AAV effectively whilst reducing treatment-related complications. 
As clinicians move towards using lower doses of induction immunosuppression in patients with 
AAV, confirming treatment-induced disease remission becomes even more important as 
unchecked smouldering inflammation can lead to the accrual of organ damage and increase 
long-term mortality. Disease activity scores such as the Birmingham Vasculitis Activity Score 
(BVAS)11 have limitations as they are often unable to distinguish active disease from 
established damage. Interval kidney biopsy is an established component of immunological 
monitoring in kidney transplantation,12 and its utility in assessing treatment response in lupus 
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nephritis is increasingly recognized.13 There are, however, few data on the use of interval 
kidney biopsy in AAV.14 
Here, we assessed the utility of initial and interval kidney biopsy in a large cohort of patients 
with ANCA-associated glomerulonephritis with long-term follow up. We defined interval kidney 
biopsy as a repeat kidney biopsy (following an initial biopsy showing active AAV) undertaken 
to determine the histological response in the kidney following induction immunosuppression. 
Specifically, we sought to determine: 1) the correlation between clinically determined and 
histologically verified disease activity during follow-up; 2) the extent to which an interval biopsy 
leads to changes in clinical management.








































































Study design & study participants
We conducted a retrospective cohort study of patients with AAV presenting to the Edinburgh 
Vasculitis Service and undergoing kidney biopsy. This met the criteria for a service evaluation 
study and hence did not require approval from a research ethics committee. All patients 
provided informed consent for treatment and received standard care according to our unit 
protocol. Patients were included if they had undergone an interval kidney biopsy. An interval 
biopsy was defined as a repeat kidney biopsy (following an initial biopsy showing active AAV) 
undertaken to determine the histological response in the kidney following induction 
immunosuppression. 
Standard of care
Within our specialist vasculitis service, induction immunosuppressive treatment for AAV 
comprises of oral glucocorticoids with either intravenous cyclophosphamide or intravenous 
rituximab, or a combination of cyclophosphamide and rituximab. Plasma exchange is used in 
some patients, mainly those with pulmonary hemorrhage or those with severe kidney 
involvement. Choice of immunosuppressive regimen is based on patient and disease factors. 
In general, patients are transitioned from induction to maintenance immunosuppression ~3 
months following diagnosis. The decision to perform an interval biopsy is made on an individual 
patient basis; these are not protocol biopsies.  
Definitions
The diagnosis of AAV was made in accordance with the 2012 Revised International Chapel 
Hill Consensus Conference Nomenclature of Vasculitides Criteria.15 Disease remission was 
defined as a BVAS of 0 for at least two months whilst taking prednisone at a daily dose of 7.5 
mg in conjunction with the treating clinician’s assessment of clinically silent disease. A major 
biopsy complication was defined as an adverse event that required hospital admission, blood 
transfusion, endovascular intervention, surgery, or resulted in death. For biopsy data analysis, 
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a crescent was defined as two or more layers of proliferating cells in Bowman’s space. A 
normal glomerulus was defined by the absence of necrosis, crescent formation, endocapillary 
proliferation and segmental or global glomerulosclerosis. Glomeruli with minor mesangial or 
ischemic changes only were included in this category. Interstitial fibrosis and tubular atrophy 
(IFTA) and interstitial nephritis were defined as mild (<25%), moderate (25-50%) and severe 
(>50%). Active AAV kidney disease on interval biopsy was defined by the presence of 
necrotizing lesions and/or cellular crescents. End-stage kidney disease (ESKD) was defined 
according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition16 as an 
estimated glomerular filtration rate (eGFR) less than 15 mL/min/1.73m2 for 3 months, dialysis 
for 3 months or receipt of a kidney transplant. 
Collection of clinical and histological data
Baseline demographic data were collected at date of initial kidney biopsy. Biochemical data 
were collected at presentation and at 12-monthly intervals to a total of 36 months follow-up. 
We accepted a range of 3 months on either side of the intended date. eGFR was calculated 
using the CKD Epidemiology Collaboration (CKD-EPI) formula. Biochemical data were also 
collected at time of interval biopsy. Urinalysis data were collected from prior to the initial and 
interval biopsy. 
All kidney biopsies were reviewed by an experienced nephropathologist. Biopsy reports were 
reviewed, and information related to glomeruli (total number and number of necrotizing lesions, 
cellular crescents, fibrocellular crescents and global glomerulosclerosis), IFTA and interstitial 
nephritis were collected. Clinical impression at time of biopsy was determined by review of 
clinical correspondence. 
Renal risk classifications were determined for all patients in accordance with the criteria 
outlined by Berden et al. and Brix et al. for both initial and interval kidney biopsies.17, 18 In brief, 
the Berden classification categorized biopsies according to whether 50% or more glomeruli on 
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biopsy were normal (focal), contained cellular crescents (crescentic) or were globally sclerosed 
(sclerotic). If there was no predominant feature, then biopsies were classified as mixed. 
Biopsies containing <10 glomeruli were excluded from Berden classification. The Brix Risk 
Score was based upon the percentage of normal glomeruli, the percentage of IFTA and the 
eGFR at time of biopsy and categorized patients into low, medium or high risk.
Statistical analysis
Data were tested for normality with log transformation as appropriate. Data are presented as 
median (interquartile range) or mean±SEM where indicated. Comparison of continuous 
variables was performed by Student’s t-test, Mann-Whitney test or Wilcoxon rank sum test as 
appropriate or mixed effects model if 3 groups with post-hoc Šídák multiple comparisons test. 
Kaplan-Meier curves analysed by Log-rank (Mantel-Cox) test. Comparison between 
categorical variables was by a Chi-square test or Fisher’s exact test where appropriate. 
Results were considered significant if two-sided p<0.05. Statistical analysis was performed 
using Prism (version 9, GraphPad Software Inc, USA) and R (version 3.4, R Foundation, 
Vienna, Austria).









































































We identified 218 patients with AAV who underwent a kidney biopsy. Of these, 57 patients 
underwent interval kidney biopsy. Of those, 55 patients had one interval kidney biopsy and two 
patients had two interval kidney biopsies. For the purposes of our analysis, the patients who 
had two interval biopsies were counted twice. Their index biopsy (showing active AAV) was 
unique to each interval biopsy.
Baseline patient demographics are shown in Table 1 and Supplementary Table S1, available 
at Rheumatology online. The median time to interval biopsy was 130 days. All patients had 
completed induction immunosuppression by the time of interval biopsy. Patients undergoing 
interval kidney biopsy were younger and were more likely to have been given a 
cyclophosphamide-based induction immunosuppression regimen and were less likely to have 
received rituximab. Compared to time of initial kidney biopsy, patients had improved 
biochemical, hematological and immunological parameters at the time of interval kidney biopsy 
(Supplementary Table S2 & Supplementary Figure S1, available at Rheumatology online). 
Of the nine patients requiring renal replacement therapy at disease presentation, only one 
patient was receiving this at the time of interval biopsy. There were no major complications 
from kidney biopsy in our cohort.
Histopathological findings
Biopsy data were available for all patients (Table 2 & Figure 1). In general, there were 
significantly more normal and globally sclerosed glomeruli on interval biopsy compared to initial 
biopsy, and fewer necrotizing lesions and crescents (both cellular and fibrocellular). All initial 
kidney biopsies had some degree of interstitial inflammation whereas ~20% of interval biopsies 
had no interstitial inflammation. There was a tendency for interval biopsies to show more 
extensive IFTA. 




































































atology/keab695/6368083 by guest on 24 Septem
ber 2021
10
Interval kidney biopsies showing active AAV (n=10) had significantly more necrotizing lesions 
and cellular crescents compared to those interval biopsies showing inactive disease (n=46) 
(Supplementary Table S3, available at Rheumatology online). Three biopsies showed a new 
pathology in the kidney; two showed membranous nephropathy and one showed a drug-
related injury. Although there was a tendency for interval biopsies with active disease to have 
more extensive interstitial inflammation than those with inactive disease, IFTA was comparable 
between the two groups. 
Clinical impression, interval biopsy findings and changes to immunosuppressive treatment
At the time of interval biopsy, 24 patients (41%) were clinically suspected to have ongoing 
disease activity; 35 patients (59%) were thought to be in clinical disease-remission. Overall, 
the clinician’s impression was incorrect in 1 in 4 biopsies (15/59) (Figure 2A). For patients with 
suspected active AAV within the kidney, this was confirmed on biopsy in only 42% (10/24) of 
cases whereas 50% (12/24) showed inactive disease and 8% (2/24) showed an alternative 
and new pathology. For patients suspected of having inactive disease, this was confirmed on 
biopsy in 97% (34/35) of cases whilst 3% (1/35) showed a new pathology. 
Following interval biopsy, immunosuppressive treatment was changed in 75% (44/59) of 
patients (Figure 2B). Importantly, 46% (11/24) of patients with previously suspected active 
disease had a reduction in immunosuppression following interval biopsy; similarly, 3% (1/35) 
of patients with previously suspected inactive disease had an escalation in 
immunosuppression. Nine patients received augmented immunosuppression. These patients 
were treated with glucocorticoid (89%), rituximab (78%), cyclophosphamide (44%) and/or 
plasma exchange (22%). All patients were treated with either rituximab or cyclophosphamide, 
and two patients were treated with both.
Change in clinical biomarkers and urinalysis at time of interval biopsy
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We went on to compare the change in biomarkers from the time of initial to interval kidney 
biopsy between patients with no evidence of disease activity (n=49) and those with active 
disease (n=10) on interval biopsy. These are biomarkers used routinely by the clinician to aid 
in the assessment of AAV disease activity (Supplementary Figure S2, available at 
Rheumatology online). Patients with inactive disease on interval biopsy had had a significant 
fall in serum creatinine (-26%) and increase in eGFR (+45%) compared to a 9% increase in 
serum creatinine and 9% fall in eGFR for those with ongoing disease activity (p<0.05 for 
between group comparisons for both). Hemoglobin had increased to a greater extent in those 
with inactive disease compared to those with active disease (+2.4 dg/L vs. +0.5 dg/L, p<0.05), 
and proteinuria had fallen to a greater extent (urine protein:creatinine: -72 mg/mmol vs. +54 
mg/mmol, p<0.05). There were no differences observed for high-sensitivity C-reactive protein 
(-88 mg/L vs. -44 mg/L, p=0.35), platelet count (-98 x109/L vs. -34 x109/L, p=0.07), MPO ANCA 
titer (-32 IU/mL vs. -28 IU/mL, p=0.91) or PR3 ANCA titer (-125 IU/mL vs. -31 IU/mL, p=0.31). 
Interestingly, hematuria, often used as a correlate of active kidney disease in AAV,19 did not 
discriminate between those with inactive or active disease on interval kidney biopsy (Figure 
3); 60% of patients with active disease on interval biopsy had no hematuria on urinalysis 
whereas 59% of patients with inactive disease on interval biopsy had some degree of 
hematuria.
Interval kidney biopsy and long-term kidney function
Of our study cohort, 55 patients had follow-up data to 12 months and 49 patients to 36 months. 
At 12 months, 7% (4/55) had reached ESKD and 4% (2/55) had died. At 36 months, these 
figures were 6% (3/49) and 8% (4/49), respectively.  
Renal risk scoring
We categorized all kidney biopsies using the Berden and Brix classification tools (Figure 4), 
respectively.17, 18 These were developed to enable prediction of long-term kidney outcome 
based on initial histopathological features, with the Brix score incorporating clinical 
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parameters. When considering all initial and interval biopsies together, and using the Berden 
Classification, there were no significant changes in the proportion classified as focal (initial vs. 
interval biopsy: 21% vs. 36%, p=0.08), sclerotic (4% vs. 15%, p=0.09) or mixed (62% vs. 49%, 
p=0.17), whereas significantly fewer interval biopsies were classified as crescentic (13% vs. 
0%, p<0.05). Using the Brix score, there were no changes in biopsies classified as low (initial 
vs. interval biopsy: 31% vs. 36%, p=0.56), medium (51% vs. 53%, p=0.85) or high risk (19% 
vs. 12%, p=0.31). 
Next, for both classification tools we evaluated how the risk classification changed between 
initial and interval biopsy for individual patients. For the Berden classification, 90% of biopsies 
(9/10) initially classified as focal remained focal on interval biopsy, with one biopsy re-classified 
as mixed. Those initial biopsies classified as crescentic became either mixed (83%, 5/6) or 
sclerotic (17%, 1/6). Fifty percent of initial biopsies (15/30) classified as mixed remained mixed 
on interval assessment with 30% (9/30) becoming focal and 20% (6/30) becoming sclerotic. 
Finally, biopsies originally classified as sclerotic either remained sclerotic (1/2) or became 
mixed (1/2) on interval classification. Using the Brix score, the majority of biopsies classified 
as low remained low (10/18) on interval assessment, whilst 39% (7/18) changed to medium 
and 6% (1/18) entered the high class. Sixty percent (18/30) of biopsies classified as medium 
remained medium on interval biopsy, whilst 33% (10/30) became low and 7% (2/30) became 
high. Of biopsies initially classified as high, the majority improved to medium (6/11) on interval 
assessment with 36% (4/11) remaining high and 9% (1/11) becoming low. 
Finally, we evaluated whether the Berden and Brix risk classification tools operated differently 
with respect to kidney outcome if calculated using interval biopsy parameters compared to 
initial biopsy parameters. For the Berden classification, and using initial biopsy data, each of 
the four groups showed an improvement in eGFR over the 36-month follow-up period (baseline 
vs. 36-month eGFR: focal, 47±7 mL/min/1.73m2 vs. 67±11 mL/min/1.73m2; crescentic, 19±5 
mL/min/1.73m2 vs. 37±10 mL/min/1.73m2; mixed, 28±4 mL/min/1.73m2 vs. 44±4 
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mL/min/1.73m2; sclerotic, 23±20 mL/min/1.73m2 vs. 35±13 mL/min/1.73m2), with no 
differences between groups (Supplementary Figure S3A, available at Rheumatology online). 
Although these figures were not significantly different using interval kidney biopsy data, there 
was a trend for the sclerotic group to show less of an increase in eGFR than those patients in 
the focal and mixed groups (Supplementary Figure S3B, available at Rheumatology online). 
For the Brix classification, the low, medium and high-risk groups all demonstrated increases 
in eGFR from baseline to 36 months (low, 42±7 mL/min/1.73m2 vs. 54±7 mL/min/1.73m2; 
medium, 30±4 mL/min/1.73m2 vs. 50±5 mL/min/1.73m2; high, 12±2 mL/min/1.73m2 vs. 30±5 
mL/min/1.73m2). Using the interval biopsy, the low and medium risk groups showed similar 
increases in eGFR over the 36-month period (low, 45±6 mL/min/1.73m2 vs. 66±6 
mL/min/1.73m2; medium, 24±3 mL/min/1.73m2  vs. 39±3 mL/min/1.73m2), however, the high-
risk group demonstrated an increase of 2 mL/min/1.73m2 (17±5 mL/min/1.73m2 vs. 19±6 
mL/min/1.73m2), significantly less than that seen using initial biopsy data (p<0.01) 
(Supplementary Figures S3C & S3D, available at Rheumatology online).








































































This is the largest study to date examining the utility of interval kidney biopsy in patients with 
AAV. We have shown that interval biopsy provides important information that guides clinical 
management of these patients. Of note, in 25% of cases the clinician’s impression of 
anticipated interval biopsy findings was incorrect. In particular, in patients where ongoing AAV 
disease activity was suspected this was confirmed in less than half of all cases. Interval biopsy 
findings may therefore prevent inappropriate escalation of immunosuppression in many 
patients. Our data also show that routinely used biomarkers of AAV disease activity, 
particularly hematuria, correlate poorly with disease activity within the kidney. We suggest that 
current renal risk prediction tools might operate more effectively using interval biopsy 
parameters. Finally, our data demonstrate the natural history of renal histopathology in AAV 
from presentation with active disease through to treatment-induced disease remission. 
The clinical utility of interval kidney biopsy is recognized in lupus nephritis. Marinaki and 
colleagues showed that interval biopsy findings modified treatment in >75% of patients,20 
findings supported by Malvar et al. who also showed that interval biopsy was safe in a study 
of 75 patients with lupus nephritis.13 To our knowledge there is only one previous study that 
has explored the role of interval kidney biopsy in patients with AAV.  Hruskova et al. reported 
on 17 patients who underwent protocolized interval biopsy.14 Similar to our own findings, they 
showed a decrease in acute lesions on interval biopsy with an increase in chronic lesions. 
Their data also suggested that the proportion of normal glomeruli remains constant throughout 
the disease process. In contrast, we found a higher proportion of normal glomeruli on interval 
biopsy. There may be a number of explanations for these differences. First, the study by 
Hruskova included younger patients (average age 49 years) with more aggressive disease on 
initial biopsy (>50% of patients had >50% cellular crescents; ~25% of patients were receiving 
dialysis) and more chronic lesions on interval biopsy.14 Second, their small study included 
patients diagnosed between 1991 and 1995, a time when AAV treatment was different to 
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current standard of care. Third, interval biopsy in their study was carried out later in the disease 
(at ~13 months compared to ~4 months in the current study).
Our study is the first to compare the change in Brix risk score and Berden Classification from 
initial kidney biopsy to interval biopsy. Brix risk score changed in ~50% of patients between 
initial and interval biopsy, ~30% of patients showed an improvement in risk score whereas the 
remaining ~20% progressed. With respect to the Berden Classification, a similar ~50% of 
patients’ biopsies changed class on interval biopsy with ~30% demonstrating progression 
(mostly from crescentic to mixed, or mixed to sclerotic), and ~20% improving, mostly from 
mixed to focal. Our data also suggest that when using these tools to predict longer-term kidney 
function at the individual patient level, data from an interval biopsy might be more useful than 
those from initial biopsy. This should be explored further in future studies. The study by 
Hruskova also examined risk categorization at both initial and interval biopsy using the Berden 
classification.14, 17 In their cohort, the majority of patients’ biopsies showed progression in 
histopathological classification, particularly from the crescentic to mixed categories. 
Our study examined routinely used clinical biomarkers of systemic and renal AAV disease 
activity. As expected, at the time of interval kidney biopsy (~4 months following initial biopsy) 
a number of these had improved compared to timing of initial biopsy. Those patients with 
inactive kidney disease demonstrated a greater reduction in serum creatinine and proteinuria, 
and rise in eGFR and hemoglobin, compared to patients with active disease on interval biopsy. 
It is interesting that CRP and PR3 (but not MPO) ANCA titre fell to a lesser extent in those with 
ongoing AAV disease within the kidney, although these did not reach significance. 
Interestingly, most (85%) patients had some degree of hematuria – often considered a marker 
of active glomerular disease – at time of interval biopsy; this includes the ~60% of patients 
subsequently shown to have inactive kidney disease. This is particularly important as currently 
defining remission is based on structured clinical assessment using validated disease activity 
scores such as the BVAS.21 This requires the treating clinician to determine whether markers 
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such as hematuria are due to active kidney disease or not. Thus, our findings suggest that 
these clinical biomarkers lack sensitivity and cannot be reliably used to discriminate active 
from inactive kidney disease in patients with AAV.  
Importantly, kidney biopsy was a safe procedure in this study. This is in keeping with a recent 
meta-analysis of over 115,000 biopsies which showed that clinically-significant bleeding 
(requiring a blood transfusion) occurs in ~1.6% of patients.22 Performing a kidney biopsy in the 
elderly, a population with a rising incidence of AAV,23 has also been shown to be safe and to 
provide important prognostic information for these patients.24 
We recognize the limitations of our study. Its retrospective nature and inclusion of patients 
from a single tertiary AAV referral centre. However, our study population is comparable in 
terms of demographics, including baseline level of kidney function, to several large randomized 
controlled trial populations, and we show similar patient outcomes.9, 25, 26 In addition, European 
Guidelines for the management of AAV now recommend patients are managed in specialist 
centers.21 Our centre does not protocolize interval kidney biopsies and decisions are based on 
a balance of benefits and risks for the individual patient. Our study was not large enough to 
answer important patient-centred questions: does the additional information gained by interval 
biopsy lead to meaningful reductions in death, ESKD and complications of 
immunosuppression such as diabetes, fractures and infections. We accept these limitations 
however it is unlikely that there will ever be a randomized trial of sufficient size to directly test 
this. Our findings contribute to the body of evidence that should be weighed to decide whether 
an interval biopsy is likely to confer more benefit or harm in any individual. 
In summary, we have examined the utility of interval kidney biopsy in patients with AAV and 
have demonstrated this to be clinically useful in determining treatment-response within the 
kidney and subsequent disease management. Interval kidney biopsy may also provide 
additional prognostic information. Our data add to the literature on the safe practice of interval 
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kidney biopsy within the contexts of kidney transplantation and lupus nephritis.12, 13, 20, 27 Given 
the vogue towards glucocorticoid-limiting, and altogether avoiding, treatment regimens, and 
with a shift towards more personalized medicine, the need for better strategies to confirm 
disease remission at the histological level is increasingly important.8-10 Our data support the 
role of interval kidney biopsy in AAV on an individual patient basis to assess disease activity.
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Figure 1: Histopathology of initial and interval kidney biopsy
Distribution of initial (red) and interval (blue) biopsy necrotizing lesions, cellular and 
fibrocellular crescents.
Figure 2: Biopsy findings and treatment change 
The biopsy findings (A) and change in immunosuppression following biopsy (B) for patients 
who were clinically suspected of active disease (n=24) or inactive disease (n=35) are shown.
Figure 3: Presence of hematuria on urinalysis
Hematuria data for patients who had an interval biopsy shown at initial biopsy (n=59) and then 
for those with active disease (n=10) and inactive disease (n=49) on interval biopsy. Analysis 
comparing active disease and inactive disease groups by Chi-square test or Fisher’s exact test 
as appropriate. No significant differences between groups.
Figure 4: Renal risk scoring
Berden risk classification (A) and Brix risk score (B) were determined for patients based on 
initial and interval biopsy. Six initial biopsies and 6 interval biopsies were excluded from Berden 
Classification as they had <10 glomeruli leaving a total of 53 biopsies for each group. All initial 
and interval biopsies were suitable for Brix risk score giving a total of 59 biopsies for each 
group. Analysis by Chi-square test or Fisher’s exact test as appropriate. 
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Table 1. Baseline demographics
Data are presented as median (interquartile range) or number of patients (%). MPO positive 
and PR3 positive refer to patients who are solely positive for that specific autoantibody. Dual 
positive refers to patients who are positive for 2 out of 3 of MPO, PR3 and GBM autoantibodies. 
eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; PCR: protein creatinine 
ratio; MPO: myeloperoxidase; PR3: proteinase 3.
Baseline characteristics Interval biopsy 
(n=59)






































Urine PCR (mg/mmol) 141 (88-312)










Time to interval biopsy (days) 130 (110-170)
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Table 2: Histopathological findings on biopsy
Data are presented as median (interquartile range) or number of patients (%). Total glomeruli 
data are presented as number of glomeruli in sample. All other glomeruli data are presented 
as percentage of normal glomeruli. Analysis by Wilcoxon matched-pairs signed rank test or 
Chi-square test as appropriate, *p <0.05. IFTA: interstitial fibrosis and tubular atrophy. 
Biopsy findings Initial biopsy(n=59)
Interval biopsy
(n=59)
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Figure 1: Histopathology of initial and interval kidney biopsy 
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Figure 2: Biopsy findings and treatment change 
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Figure 3: Presence of hematuria on urinalysis 
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Figure 4: Renal risk scoring 
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